FUNDAMENTAL & CLINICAL PHARMACOLOGY

Scope & Guideline

Elevating the standards of pharmacological research and clinical application.

Introduction

Explore the comprehensive scope of FUNDAMENTAL & CLINICAL PHARMACOLOGY through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore FUNDAMENTAL & CLINICAL PHARMACOLOGY in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN0767-3981
PublisherWILEY
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1987 to 2024
AbbreviationFUND CLIN PHARMACOL / Fundam. Clin. Pharmacol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

FUNDAMENTAL & CLINICAL PHARMACOLOGY aims to bridge the gap between fundamental pharmacological research and clinical applications. The journal focuses on the pharmacological aspects of drug therapy, including mechanisms of action, therapeutic efficacy, and safety profiles in various populations.
  1. Pharmacological Mechanisms and Drug Actions:
    This area encompasses studies that investigate the biochemical and molecular mechanisms through which drugs exert their effects, including receptor interactions, signaling pathways, and pharmacodynamics.
  2. Clinical Pharmacology and Therapeutics:
    Research focusing on the clinical implications of pharmacotherapy, including the efficacy and safety of drugs in specific patient populations, therapeutic drug monitoring, and the optimization of dosing regimens.
  3. Pharmacovigilance and Drug Safety:
    The journal emphasizes the importance of pharmacovigilance, reporting adverse drug reactions, and monitoring drug safety in clinical practice, particularly in vulnerable populations.
  4. Pharmacogenetics and Personalization of Therapy:
    Studies exploring genetic factors influencing drug metabolism and response, aiming to tailor pharmacotherapy to individual patient profiles for better outcomes.
  5. Innovative Drug Development and Therapeutic Strategies:
    Research on new therapeutic agents, drug repurposing, and innovative approaches to enhance treatment efficacy and minimize side effects.
  6. Epidemiology and Public Health:
    This scope includes studies assessing drug utilization patterns, the impact of drug policies on public health, and the epidemiological trends of drug-related issues.
Emerging trends in FUNDAMENTAL & CLINICAL PHARMACOLOGY reflect a growing interest in personalized medicine, advanced therapeutic strategies, and the integration of pharmacogenomics into clinical practice. These areas are increasingly relevant as the field evolves to address contemporary health challenges.
  1. Personalized Medicine and Pharmacogenomics:
    There is a marked increase in research focusing on tailoring pharmacotherapy based on genetic profiles, emphasizing the need for personalized approaches to enhance drug efficacy and minimize adverse effects.
  2. Real-World Evidence and Pragmatic Trials:
    Growing interest in studies that evaluate drug effectiveness and safety in real-world settings, moving beyond controlled clinical trials to understand how drugs perform in diverse patient populations.
  3. Immunotherapy and Biologics:
    Research into immunotherapy, particularly the use of monoclonal antibodies and checkpoint inhibitors, is expanding, reflecting an increasing recognition of their potential in treating various conditions, including cancer.
  4. Digital Health and Pharmacovigilance Technologies:
    Emerging technologies for monitoring drug safety and efficacy, including mobile health applications and artificial intelligence, are gaining traction as tools for enhancing pharmacovigilance.
  5. Neuropharmacology and Mental Health:
    There is a rising focus on the pharmacological management of mental health disorders, exploring novel therapeutic agents and their mechanisms of action in neurological contexts.

Declining or Waning

While FUNDAMENTAL & CLINICAL PHARMACOLOGY continues to expand its research frontiers, certain themes have become less prominent in recent years. This decline may reflect shifting research priorities or advancements in other areas of pharmacology.
  1. Traditional Herbal Medicine:
    Research on herbal medicines and their pharmacological effects has seen a decline, possibly due to the increasing focus on synthetic drugs and biologics that provide more consistent results in clinical settings.
  2. Basic Toxicology Studies:
    While toxicology remains a crucial area, the focus on basic toxicological mechanisms has waned in favor of more applied studies that directly address clinical implications and drug safety.
  3. Animal Models of Drug Action:
    Although animal studies are still important, there has been a shift towards human-based research and clinical trials, with less emphasis on preclinical animal models compared to previous years.
  4. Drug Formulation Studies:
    Research focused solely on the formulation aspects of drug development has decreased, as the field moves towards integrated approaches that combine formulation with clinical efficacy and safety assessments.

Similar Journals

PHARMACOTHERAPY

Transforming Pharmacological Science for Tomorrow
Publisher: WILEYISSN: 0277-0008Frequency: 12 issues/year

PHARMACOTHERAPY, an esteemed journal published by WILEY, stands as a pivotal resource within the field of medical pharmacology. With its ISSN 0277-0008 and E-ISSN 1875-9114, this journal has been at the forefront of pharmacological research since its inception in 1981. Renowned for its rigorous peer-review process and impactful contributions, it currently holds a prestigious Q1 quartile ranking in the pharmacology category, underscoring its significance as a leading publication in the field. It ranks #40 out of 272 journals in Scopus, placing it in the top 15% percentile of its category. While not an open-access publication, PHARMACOTHERAPY remains committed to advancing knowledge and understanding in pharmacological sciences, making it an indispensable resource for researchers, healthcare professionals, and students dedicated to improving therapeutic outcomes and drug utilization. Based in the United States, at 111 River St, Hoboken, NJ, the journal is poised to continue its impact through to 2024 and beyond, welcoming contributions that further the discourse in pharmacotherapy.

FARMACIA

Unveiling Insights in Pharmacotherapy and Beyond.
Publisher: SOC STIINTE FARMACEUTICE ROMANIAISSN: 0014-8237Frequency: 6 issues/year

FARMACIA is a renowned academic journal published by the SOC STIINTE FARMACEUTICE ROMANIA, specializing in the field of pharmacology, toxicology, and pharmaceutics. With a rich history dating back to its initial publication years of 1945 to 1946, and ongoing contributions since 2008, the journal has established itself as a significant platform for disseminating cutting-edge research in the pharmaceutical sciences. Indexed in Scopus, it holds a commendable Q2 ranking in the Pharmacology, Toxicology and Pharmaceutics category, reflecting its importance in the field. The journal aims to foster knowledge sharing and innovation among researchers, professionals, and students alike, making it an essential resource for advancing pharmaceutical research. Although it does not currently offer Open Access, the content is accessible to a broad academic audience, ensuring valuable insights into current trends and discoveries in pharmacotherapy and drug development. For those seeking a deeper understanding of the evolving landscape of pharmaceutical sciences, FARMACIA provides a critical lens through which to explore and engage with the latest scientific advancements.

CLINICAL THERAPEUTICS

Advancing pharmacological innovation for better patient outcomes.
Publisher: ELSEVIERISSN: 0149-2918Frequency: 12 issues/year

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Unveiling the science behind effective therapeutics.
Publisher: DUSTRI-VERLAG DR KARL FEISTLEISSN: 0946-1965Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany, is a vital scholarly platform dedicated to advancing the field of pharmacology through rigorous research and innovative therapeutic strategies. Established in 1994, this journal has maintained its relevance in the evolving landscape of clinical pharmacology, achieving a Q3 rank in both general and medical pharmacology categories as of 2023. With an ISSN of 0946-1965, it is positioned as an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding of drug therapy and pharmacological applications. Though it currently does not offer open access, its comprehensive scope covers a wide array of topics within pharmacology, promising to contribute significantly to scientific discussions and knowledge dissemination from 1994 to 2024. Whether you are looking for the latest studies or historical insights, the journal remains a fixture for anyone invested in the pharmacological sciences.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Navigating the Complexities of Drug Action and Toxicity
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Exploring Innovations in Pharmacological Science
Publisher: WILEYISSN: 0306-5251Frequency: 12 issues/year

British Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.

Frontiers in Pharmacology

Unlocking the potential of pharmacology through open access.
Publisher: FRONTIERS MEDIA SAISSN: Frequency: 1 issue/year

Frontiers in Pharmacology, published by FRONTIERS MEDIA SA, stands as a leading open-access journal dedicated to advancing the field of pharmacology since its inception in 2010. With its ISSN 1663-9812, the journal is based in Switzerland and maintains a vital role in disseminating innovative research findings that span various disciplines within pharmacology, including pharmacokinetics, toxicology, and pharmacogenetics. In 2023, Frontiers in Pharmacology has achieved an impressive standing within the scientific community, being ranked in the Q1 category for both general and medical pharmacology, highlighting its critical contribution to the field with a Scopus ranking of #41 out of 272 in medical pharmacology and #76 out of 313 in pharmacology, toxicology, and pharmaceutics, placing it in the 75th and 85th percentiles, respectively. Researchers and practitioners benefit from its open-access model, which ensures widespread accessibility to groundbreaking research, fostering collaboration and innovation across the pharmaceutical sciences. With its commitment to excellence, Frontiers in Pharmacology serves as an essential resource for those looking to explore and contribute to the latest advancements in pharmacological research.

International Journal of Pharmaceutical Investigation

Driving Innovation in Drug Development and Formulation
Publisher: INPHARM ASSOC, PHCOG NETISSN: 2230-973XFrequency: 4 issues/year

International Journal of Pharmaceutical Investigation, published by INPHARM ASSOC, PHCOG NET, is a premier platform dedicated to advancing the field of pharmaceutical sciences. With the ISSN 2230-973X and E-ISSN 2230-9713, this journal serves as a vital resource for researchers, professionals, and students focused on drug development, formulation, and efficacy. By fostering a rich discourse on innovative pharmaceutical practices and research breakthroughs, the journal plays a critical role in enhancing global health outcomes through groundbreaking scholarly work. The absence of open access allows for selective dissemination of high-quality content, promoting rigorous peer-review processes that uphold academic integrity. Featuring articles that span a diverse range of topics within pharmaceutical sciences, the International Journal of Pharmaceutical Investigation is committed to supporting the ongoing evolution of this dynamic field, making it an essential read for anyone engaged in pharmaceutical research and development.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Transforming vision care with cutting-edge studies.
Publisher: MARY ANN LIEBERT, INCISSN: 1080-7683Frequency: 10 issues/year

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.

ANNALS OF PHARMACOTHERAPY

Pioneering Discoveries in Drug Therapy and Application
Publisher: SAGE PUBLICATIONS INCISSN: 1060-0280Frequency: 12 issues/year

ANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.